Jul 27, 2026 09:00AM
Dec 7, 2025 12:01PM
Sep 26, 2025 07:02AM
Sep 26, 2025 07:00AM
Sep 16, 2025 02:00AM
Jun 16, 2025 07:48PM
Apr 29, 2025 07:07AM Travere Therapeutics (TVTX) and CSL Vifor Announce Standard EU Approval of FILSPARI (sparsentan) for IgA Nephropathy
Apr 29, 2025 07:01AM
Mar 3, 2025 08:00AM
Feb 7, 2025 09:12AM
Oct 17, 2024 02:30AM
Jul 9, 2024 09:00AM
May 7, 2024 04:00PM
May 2, 2024 09:30AM Recently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons
Mar 28, 2024 03:00AM
Mar 6, 2024 09:00AM
Feb 23, 2024 07:06AM
Feb 23, 2024 07:05AM
Feb 23, 2024 02:00AM
Jan 16, 2024 08:00AM
Jan 3, 2024 08:00AM CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe
Jan 2, 2024 08:00AM
Dec 14, 2023 02:47PM
Dec 11, 2023 07:30PM
Oct 27, 2023 10:00AM
Oct 11, 2023 08:30AM
Sep 19, 2023 04:50AM
Aug 28, 2023 08:30AM CSL Seqirus Announces Third U.S. Government Award in Relation to Influenza A(H5N8) Candidate Vaccine
Jul 17, 2023 08:30AM
Jun 20, 2023 07:09AM
Jun 20, 2023 07:05AM
Jun 20, 2023 07:00AM
Jun 5, 2023 09:00AM
May 2, 2023 09:00AM
Apr 18, 2023 09:00AM CSL Behring Receives FDA Approval for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 50mL Prefilled Syringe
Mar 1, 2023 08:00AM
Feb 26, 2023 10:45AM
Feb 23, 2023 08:00AM
Feb 20, 2023 04:42PM
Dec 16, 2022 07:16AM
Dec 16, 2022 07:15AM
Dec 10, 2022 10:00AM CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treat
Nov 22, 2022 04:40PM
Nov 22, 2022 04:40PM
Nov 22, 2022 04:21PM
Nov 22, 2022 03:59PM
Nov 2, 2022 06:30PM
Oct 6, 2022 12:00PM
Sep 26, 2022 08:00AM New Real-World Data Presented at OPTIONS XI Show Cell-Based and MF59®-Adjuvanted Influenza Vaccines Can Reduce the Burden of Seasonal Influenza on Hospitals and Health Systems
Sep 8, 2022 08:05AM

326,549 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All